University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu
Thomas Jefferson University - Linda D. Siracusa, PhD
Linda D. Siracusa, PhD

Microbiology & Immunology
Thomas Jefferson University
Jefferson Medical College
Department of Microbiology and Immunology
Professor

Image Placeholder
Mailing Address
233 South 10th Street, BLSB 719
Philadelphia, Pennsylvania 19107-5541
United States
Contact Information
Phone: 215-503-4536
Fax: 215-923-4153
Siracusa@mail.jci.tju.edu
Qualifications
Ph.D.
Expertise and Research Interests
The study of genes that influence complex traits is a rapidly evolving field. The power of mammalian genetics coupled with the ability to scan entire genomes of individual animals has led to the discovery of chromosomal regions that harbor genes conferring susceptibility or resistance to different cancers. My laboratory focuses on identifying and characterizing genes that influence the development of cancer along the gastrointestinal tract. Our research combines molecular biology and classical genetics to investigate cancer susceptibility genes. Specifically, we focus on selected crosses between mouse mutations and inbred strains to determine the chromosomal location of modifier loci. We then screen candidate genes in each region and use transgenesis to prove the identity of novel modifier genes. Our goal is to understand the mechanisms of tumor suppression.

The system we chose involves the tumor suppressor gene Adenomatous Polyposis Coli (APC). Mutations in the human APC gene are responsible for the majority of inherited and sporadic colorectal cancers. Min mice have a mutation in the murine homologue of the human APC gene and develop multiple adenomas along their intestinal tract. Quantitative trait locus (QTL) studies identified a locus, Modifier of Min 1 (Mom1), which maps to the distal region of mouse chromosome 4. The Mom1 locus dramatically affects ApcMin-induced tumor number. We were the first to report that the secretory type II Phospholipase A2 (Pla2g2a) gene is a strong candidate for the Mom1 locus. Inbred mouse strains display 100% concordance between Pla2g2a allele type and tumor susceptibility. Expression and sequence analysis showed that Mom1 susceptible strains carry null alleles of the Pla2g2a gene. We developed a fluorescent enzyme activity assay for Pla2g2a which confirms and extends our molecular and immunohistochemical findings. Studies are in progress to establish the mechanism by which Pla2g2a prevents intestinal polyp formation as well as to investigate the role of PLA2G2A in human neoplasia and intestinal homeostasis.

We recently discovered a spontaneous dominant mutation, Modifier of Min 2 (Mom2), which is a potent suppressor of intestinal and colorectal tumorigenesis in ApcMin mice. One copy of the resistant Mom2R allele reduces small intestine adenoma numbers and colon adenoma incidence by ~90% in ApcMin mice. We localized Mom2 to the distal end of mouse chromosome 18 using a unique exclusion mapping strategy. Recent work combining quantitative RT-PCR and sequencing revealed a 4 bp duplication within exon 3 of the ATP synthase (Atp5a1) gene that is responsible for the Mom2 phenotype. Studies of tumor suppression are suggesting a novel mechanism of cellular lethality that is specific to the tumor lineage, which results in the suppression of polyp development. Further work is ongoing to understand the full effects of Mom2 on adenoma initiation, growth, and progression. Our work on this system is performed in collaboration with the laboratory of Dr. Arthur Buchberg at the Kimmel Cancer Center.

We have also established several reciprocal congenic lines of mice between the C3H/HeJ and C57BL/6J inbred strains that have a resistant Mom1 locus on an otherwise susceptible background and a susceptible Mom1 locus on an otherwise resistant background. Testing of these congenic lines has demonstrated significant differences in polyp formation in both the small and large intestines. Using these new congenic strains in designer crosses, offspring are aged and analyzed for tumor number, size and position and QTL analyses is performed to identify chromosomal regions that contain genes which act to significantly decrease polyp formation. We completed the first large-scale backcross to identify new modifier loci. Microarray analyses will determine gene expression profiles of existing and future lines to determine pathways that are prime candidates for conferring resistance phenotypes. We are using a similar strategy to assess the impact of the evolutionarily divergent Mus castaneus (CAST) genetic background on intestinal and colorectal tumorigenesis.

The comprehensive examination of novel modifier loci in humans will facilitate an understanding of the relationship between the effects of modifier genes on tumor initiation, growth, and progression. Further investigations will lead to insights about the role of modifier genes in human cancer risk assessment, tumor prevention, diagnosis, and their predictive value for response to treatment.

We recently predicted that microRNAs are candidates for tumor susceptibility genes. To this end, we established a database comparing the positions of mouse microRNAs across the genome with the positions of loci conferring susceptibility to eight different solid tumors. We established the MUSMIRSUS database (http://www.kimmelcancercenter.org/siracusa/musmirsus.htm) which compares the positions of tumor susceptibility loci with the positions of microRNAs in the mouse genome. Statistical analyses revealed a highly significant (p<0.001) association between the presence of microRNA genes and the locations of tumor susceptibility loci. Comparisons of the sequence of microRNAs between inbred strains that are known to differ in their resistance or susceptibility to specific types of tumors revealed polymorphisms, primarily in the regions upstream of the microRNA stem-loop structure. Studies are continuing to assess the level of expression of microRNAs in tissues of the gastrointestinal tract, in both normal and disease states. This research is performed in collaboration with Dr. Carlo Croce and Dr. George Calin at Ohio State University Medical Center.
Keywords
Cancer Risk; Cancer Genetics; Colorectal Cancer; Digestive Diseases and Disorders; Gastrointestinal System; Gene Expression; Gene Mutation; Genetic Library; Genetic Model; Immunohistochemistry; Laboratory Mouse; Mammalian Genetics; Model Design Development; Molecular Cloning; Molecular Oncology; Molecular Pathology; Nucleic Acid Sequence; Phenotype; Pleiotropism; Polymerase Chain Reaction; Protein Structure Function; Pulsed Field Gel Electrophoresis; Small Intestine; Southern and Northern Blotting; Tissue Cell Culture; Transcription; Transgenic Animals; Tumor Progression; Western Blotting
Publications
  • Silverman, K.A., Koratkar, R., Siracusa, L.D. & A.M. Buchberg. Identification of the Modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Research 12: 88-97, 2002.
  • Koratkar, R., Pequignot, E., Hauck, W.W. & L.D. Siracusa. The CAST/Ei strain confers significant protection against ApcMin-intestinal polyps, independent of the resistant Modifier of Min 1 (Mom1R) locus. Cancer Research 62: 5413-5417, 2002.
  • Silverman, K.A., Koratkar, R., Siracusa, L.D. & A.M. Buchberg. Exclusion of Madh2, Madh4, and Madh7 as candidates for the Modifier of Min 2 (Mom2) locus. Mammalian Genome 14: 119-129, 2003.
  • Ghiselli, G., Coffee, N., Munnery, C.E., Koratkar, R. & L.D. Siracusa. The cohesin SMC3 is a target for the B-catenin/Tcf4 transactivation pathway. J. Biol. Chem. 278: 20259-20267, 2003.
  • Siracusa, L.D., Silverman, K.A., Koratkar, R., Markova, M. & Buchberg, A.M. Genome-wide modifier screens: How the genetics of cancer penetrance may shape the future of prevention and treatment. In Oncogenomics: Molecular Approaches to Cancer (C. Brenner and D. Duggan, editors) John Wiley & Sons, Inc. New York, NY. pp. 255-290, 2004.
  • Cha, K.B., Karolyi, I.J., Hunt, A., Frank, R., Wenglikowski, A.M., Wilkinson, J.E., Dolan, D.F., Dootz, G., Finnegan, A.A., Hankenson, K., Siracusa, L.D. & S.A. Camper. Skeletal dysplasia and male infertility locus on mouse chromosome 9. Genomics 83: 951-960, 2004.
  • Koratkar, R., Silverman, K.A., Pequignot, E., Hauck, W.W., Buchberg, A.M. & L.D. Siracusa. Analysis of reciprocal congenic strains reveals the C3H/HeJ genome to be highly resistant to ApcMin intestinal tumorigenesis. Genomics 84: 844-852, 2004.
  • Markova, M., Zeskand, J., McEntee, B., Rothstein, J., Jimenez, S.A. & L.D. Siracusa. A role for the androgen receptor in collagen content of the skin. Journal of Investigative Dermatology 123: 1052-1056, 2004.
  • Markova, M., Koratkar, R.A, Silverman, K.A., Sollars, V.E., MacPhee-Pellini, M., Walters, R., Palazzo, J., Buchberg, A.M., Siracusa, L.D. & S.A. Farber. Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to ApcMin/+ tumorigenesis. Oncogene 24: 6450-6458, 2005.
  • Herron, B.J., Liddell, R.A., Parker, A., Grant, S., Kinne, J., Fisher, J.K. & L.D. Siracusa. A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice. Nature Genetics 37: 1210-1212, 2005.
  • Sevignani, C., Calin, G., Siracusa, L.D. & C.C. Croce. Mammalian MicroRNAS: A small world for fine-tuning gene expression. Mammalian Genome 17: 189-202, 2006.
  • Baran, A.A., Silverman, K.A., Zeskand, J., Koratkar, R., Palmer, A., McCullen, K., Curran, W.Jr., Bocker-Edmonston, T., Siracusa, L.D. & A.M. Buchberg. Characterization of the Modifier of Min 2 (Mom2) locus: The embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression. Genome Research 17: 566-576, 2007.
  • Sevignani, C., Calin, G.A., Nnadi, S.C., Shimizu, M., Davuluri, R.V., Hyslop, T., Demant, P., Croce, C.M. & L.D. Siracusa. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc. Natl. Acad. Sci. USA 104: 8017-8022, 2007.
  • Li, P., Schulz, S., Bombonati, A., Palazzo, J.P., Hyslop, T.M., Xu, Y., Baran, A.A., Siracusa, L.D., Pitari, G.M. & S.A. Waldman. Guanylyl Cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133: 599-607, 2007.
  • Rossi, S., Sevignani, C., Nnadi, S.C., Siracusa, L.D. & G.A. Calin. Cancer-associated genomic regions (CAGRs) and non-coding RNAs: Bioinformatics and therapeutic implications. Mammalian Genome 19: 526-540, 2008.
  • Siracusa, L.D. & A.M. Buchberg. The noncoding RNAs: a genomic symphony of transcripts. Mammalian Genome 19: 449-453, 2008.

Individual Expertise profile of Linda D. Siracusa, PhD, Copyright © Linda D. Siracusa, PhD.
Last Updated by Linda Siracusa, PhD : Thursday, August 27, 2009 2:03:11 PM



 Printable Version

Thomas Jefferson University
Thomas Jefferson University